SAREPTA THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Debt, Net of Issuance Costs of $29.62 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-10-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2018-10-31
- SAREPTA THERAPEUTICS, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from debt, net of issuance costs for the quarter ending 2015-09-30 was -$133.00K.
- SAREPTA THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2015 was $19.60M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2017-09-30 | $29.62M 10-Q · filed 2018-10-31 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$133.00K derived: sum of 2 quarters · filed 2017-02-28 | $19.60M 10-K · filed 2017-02-28 | |
| 2015-09-30 | -$133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $19.60M 10-Q · filed 2016-11-07 | ||
| 2015-06-30 | $19.73M 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |